Racura Oncology (RAC) investor relations material

Executive summary

• (E,E)-bisantrene discovered to act by binding to G4-DNA & RNA, not as a doxorubicin-like chemotherapeutic, fundamentally transforming commercial and clinical opportunities.

• Clinical programs expanded for RC220 in lung cancer, solid tumours, and acute myeloid leukaemia, targeting major cancer markets.

• Composition of matter patent claims filed for (E,E)-bisantrene, potentially providing 20 years of protection.

• Appointment of Prof. Laurence Hurley to Scientific Advisory Board, strengthening expertise in G4-targeting drugs.

• Company name changed from Race Oncology Limited to Racura Oncology Ltd.

Financial highlights

• Cash and cash equivalents of $20.94 million at 31 December 2025.

• Private placement raised $3.22 million at a premium to market; early option conversions added $5.62 million.

• R&D and drug manufacturing accounted for over 63% of spending ($1.35 million) in the quarter.

• Received $2.79 million R&D Tax Incentive from the Australian Taxation Office for FY2025.

Outlook and guidance

• Funding secured to support all committed activities through calendar year 2027.

• HARNESS-1 Phase 1a/b trial in EGFRm NSCLC to commence in early 2026, with additional sites to be activated in H1 CY2026.

• Preclinical collaboration with Emory University to study (E,E)-bisantrene in osimertinib-resistant NSCLC expected to last over 12 months.